KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Teva Pharmaceutical Industries (TEVA) Divestments (2020 - 2026)

Teva Pharmaceutical Industries filings provide 7 years of Divestments readings, the most recent being $42.0 million for Q1 2026.

On a quarterly basis, Divestments rose 147.06% to $42.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $59.0 million, a 1.67% decrease, with the full-year FY2025 number at $34.0 million, down 20.93% from a year prior.
Divestments hit $42.0 million in Q1 2026 for Teva Pharmaceutical Industries, up from $8.0 million in the prior quarter.
In the past five years, Divestments ranged from a high of $56.0 million in Q2 2023 to a low of $1.0 million in Q2 2024.
Median Divestments over the past 5 years was $13.5 million (2023), compared with a mean of $18.2 million.
Biggest five-year swings in Divestments: crashed 98.21% in 2024 and later skyrocketed 800.0% in 2025.
Teva Pharmaceutical Industries' Divestments stood at $23.0 million in 2022, then tumbled by 56.52% to $10.0 million in 2023, then plummeted by 60.0% to $4.0 million in 2024, then skyrocketed by 100.0% to $8.0 million in 2025, then skyrocketed by 425.0% to $42.0 million in 2026.
The last three reported values for Divestments were $42.0 million (Q1 2026), $8.0 million (Q3 2025), and $9.0 million (Q2 2025) per Business Quant data.